Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Alliance for Clinical Trials in Oncology524 enrolled

Overview

This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rituximab together with combination chemotherapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective when given with rituximab in treating diffuse large B-cell non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.

PRIMARY OBJECTIVES: I. To compare the event-free survival of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone (R-CHOP) versus dose-adjusted (DA-) etoposide, prednisone, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, and rituximab (EPOCH-R) chemotherapy in untreated cluster of differentiation (CD)20 positive (+) diffuse large B-cell lymphomas. II. To develop a molecular predictor of outcome of R-CHOP and DA-EPOCH-R chemotherapy using molecular profiling. SECONDARY OBJECTIVES: I. To compare the response rates, overall survival and toxicity of R-CHOP versus DA-EPOCH-R. II. To define the pharmacogenomics of untreated diffuse large B-cell lymphoma (DLBCL) and correlate clinical parameters (toxicity, response, survival outcomes and laboratory results) with molecular profiling. III. To assess the use of molecular profiling for pathological diagnosis. IV. To identify new therapeutic targets using molecular profiling. V. To perform a comprehensive analysis of somatic alterations to the tumor genome and to understand which genomic alterations are somatically acquired by the tumor and which are encoded in the germ line of the patient. VI. To identify biomarkers of response to chemotherapy by fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging that are predictive of histopathologic remissions and survival in patients with stage I (mediastinal), II, III, or IV untreated DLBCL. VII. To evaluate the use of semiquantitative measurements of FDG uptake in defining FDG-PET/CT based biomarkers of response to chemotherapy in patients with DLBCL. VIII. To determine whether FDG-PET/CT measurements of tumor response after the second cycle of chemotherapy can predict clinical response. IX. To establish a standardized protocol for FDG-PET/CT image acquisition. X. To determine additional FDG-PET/CT parameters (e.g., the ratio of tumor maximum standard uptake value \[SUVmax\] to liver SUVmean; SUVs corrected for body surface area and lean body mass; nuclear medicine physician's assessment) and evaluate their utility in refining FDG-PET/CT based biomarkers of response to therapy. XI. To evaluate inter-institutional reproducibility of FDG-PET/CT measurements for this indication. OUTLINE: Patients are randomized to 1 of 2 treatment arms.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

1. Histologically documented de novo CD20+ DLBCL with stage II, III or IV disease. * Stage I primary mediastinal (thymic) DLBCL is also eligible. * Patients with an underlying low-grade lymphoma, such as a transformed lymphoma or low-grade lymphoma in the bone marrow, are not eligible. * Diagnosis should be based on an adequate tissue sample, including open biopsy or core needle biopsy. * Needle aspiration for primary diagnosis is unacceptable. * Patients must have one of the following WHO classification subtypes: * Diffuse large B-cell lymphoma (includes morphological variants: centroblastic, immunoblastic, T-cell/histiocyte rich, and anaplastic) * Mediastinal (thymic) large B-cell lymphoma * Intravascular large B-cell lymphoma * Note: Failure to submit a pathology block within 60 days of patient registration will be considered a major protocol violation. * Fresh (frozen) tumor biopsy must be available or attempted. A frozen tumor biopsy equivalent to a minimum of four at least 16 gauge needle cores is an important component of this study. * Patients without adequate frozen material should have a biopsy performed to obtain material. * If a biopsy is performed and does not yield adequate material, the patient is still eligible for the study. If a biopsy cannot be done safely, the patient may still be eligible for the study if permission is granted. * Note: This study does not allow concurrent radiation unless a patient has a documented CNS treatment failure with no systemic failure. 2. No prior cytotoxic chemotherapy or rituximab. Patients may be entered if they have received prior limited field radiation therapy or a short course of glucocorticoids (\< 10 days) for an urgent local disease complication at diagnosis (e.g., cord compression, SVC syndrome). Patients who have received chemotherapy for prior malignancies are not eligible. 3. Age ≥ 18 years 4. ECOG Performance Status 0-2 5. No active ischemic heart disease or congestive heart failure. If there is suspicion of cardiac disease, a cardiac ejection fraction must show LVEF \> 45%, but the study is not required 6. No known lymphomatous involvement of the CNS. A lumbar puncture prior to study is not required in the absence of neurological symptoms 7. No known HIV disease. Patients with a history of intravenous drug abuse or any other behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus. Patients who test positive or who are known to be infected are not eligible. 8. Non pregnant and non-nursing. Treatment would expose an unborn child to significant risks. Women and men of reproductive potential should agree to use an effective form of contraception. 9. Patients with active medical processes (e.g., uncontrolled bacterial or viral infection, bleeding) not related to their lymphoma should be excluded. 10. Required Initial Laboratory Values (unless non-Hodgkin lymphoma): * ANC ≥ 1000/μL * Platelets ≥ 100,000/μL * Creatinine≤ 1.5 mg/dL or creatinine clearance ≥ 50 cc/min * Total Bilirubin ≤ 2 mg/dL (unless a history of Gilbert's Disease)

Locations (47)

Rebecca and John Moores UCSD Cancer Center

La Jolla, California, United States

Camino Medical Group - Treatment Center

Mountain View, California, United States

Palo Alto Medical Foundation

Palo Alto, California, United States

Naval Medical Center - San Diego

San Diego, California, United States

Saint Helena Hospital

St. Helena, California, United States

Outcomes

Primary Outcomes

Progression-Free Survival Rate at 2 and 5 Years

Progression-free survival (PFS) is defined as the time from randomization to progression, relapse, or death from any cause, whichever occurred first. Progression (PD) or Relapse\> * ≥ 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders.\> * Appearance of any new lesion during or after completion of therapy.\> * PET+ is not a criterion for progressive disease. Patients only with PET+ findings must have evidence of progression on CT or biopsy proven.\> The PFS rate (percentage of participants who are alive and progression-free) at 2 and 5 years Kaplan Meier estimates and 95% Confidence Intervals are reported below.

Time frame: Up to 5 years post-registration

Secondary Outcomes

Response Rate

The overall response rate is defined as the percentage of participants with a response (Complete Response or Partial Response)

Time frame: Up to 5 years post-registration

Overall Survival Rate at 2 and 5 Years

Overall survival is defined as the time from randomization to death due to any cause. The overall survival (OS) rate (percentage of participants who are still alive) at 2 and 5 years Kaplan Meier estimates and 95% confidence intervals are reported below.

Time frame: Up to 5 years post-registration

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Overview

Conditions

Interventions

Eligibility

Locations (47)

Outcomes

Primary Outcomes

Secondary Outcomes